Abstract
Extracellular vesicles (EV) released by various types of cells are detectable in body fluids such as blood and urine. Both clinical and animal studies showed that circulating EVs were elevated in response to many types of liver diseases, such as hepatocellular carcinoma (HCC), nonalcoholic fatty liver disease, acute liver failure, liver cirrhosis, hepatic ischemia-reperfusion (I/R) injury, and drug-induced liver injury. The increase in subgroups of EVs and certain EV molecules was found to be of diagnostic and prognostic value for some liver diseases such as HCC and liver cirrhosis. Some microRNA species were solely increased in serum EVs but not the whole serum under disease states, indicating that circulating EVs may provide more sensitive liver biomarkers. Blood EVs from patients appeared to play a detrimental role contributing disease progression. Blocking blood EV elevation by pharmacological approaches afforded protection against liver damage. Circulating EVs are emerging as a rich source of new biomarkers for liver diseases.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- ALF:
-
Acute liver failure
- ALT:
-
Alanine aminotransferase
- AFP:
-
Alpha-fetoprotein
- ASGPR1:
-
Asialoglycoprotein receptor
- DILI:
-
Drug-induced liver injury
- EV:
-
Extracellular vesicles
- HepB:
-
Hepatitis B
- HepC:
-
Hepatitis C
- HCC:
-
Hepatocellular carcinoma
- I/R:
-
Ischemia-reperfusion
- NAFLD:
-
Nonalcoholic fatty liver disease
- NASH:
-
Nonalcoholic steatohepatitis
- ROCK1:
-
Rho-associated, coiled-coil-containing protein kinase 1
References
Andaloussi ELA, Mager I, Breakefield XO, et al. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013;12:347–57.
Brodsky SV, Facciuto ME, Heydt D, et al. Dynamics of circulating microparticles in liver transplant patients. J Gastrointestin Liver Dis. 2008;17:261–88.
Conde-Vancells J, Rodriguez-Suarez E, Embade N, et al. Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes. J Proteome Res. 2008;7:5157–66.
Freeman CM, Quillin 3rd RC, Wilson GC, et al. Characterization of microparticles after hepatic ischemia-reperfusion injury. PLoS One. 2014;9:e97945.
Gould SJ, Raposo G. As we wait: coping with an imperfect nomenclature for extracellular vesicles. J Extracell Vesicles. 2013;2:201389.
Hirsova P, Ibrahim SH, Krishnan A, et al. Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes. Gastroenterolog. 2016;150:956–67.
Keerthikumar S, Chisanga D, Ariyaratne D, et al. ExoCarta: a web-based compendium of exosomal cargo. J Mol Biol. 2016;428:688–92.
Kornek M, Lynch M, Mehta SH, et al. Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology. 2012;143:448–58.
Lemoinne S, Thabut D, Housset C, et al. The emerging roles of microvesicles in liver diseases. Nat Rev Gastroenterol Hepatol. 2014;11:350–61.
Li Y, Zhang L, Liu F, et al. Identification of endogenous controls for analyzing serum exosomal miRNA in patients with hepatitis B or hepatocellular carcinoma. Dis Markers. 2015;2015:893594.
Liu WH, Ren LN, Wang X, et al. Combination of exosomes and circulating microRNAs may serve as a promising tumor marker complementary to alpha-fetoprotein for early-stage hepatocellular carcinoma diagnosis in rats. J Cancer Res Clin Oncol. 2015;141:1767–78.
Povero D, Eguchi A, Li H, et al. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PLoS One. 2014;9:e113651.
Rautou PE, Bresson J, Sainte-Marie Y, et al. Abnormal plasma microparticles impair vasoconstrictor responses in patients with cirrhosis. Gastroenterology. 2012;143:166–76.
Rodriguez-Suarez E, Gonzalez E, Hughes C, et al. Quantitative proteomic analysis of hepatocyte-secreted extracellular vesicles reveals candidate markers for liver toxicity. J Proteomics. 2014;103:227–40.
Royo F, Schlangen K, Palomo L, et al. Transcriptome of extracellular vesicles released by hepatocytes. PLoS One. 2013;8:e68693.
Schmelzle M, Splith K, Andersen LW, et al. Increased plasma levels of microparticles expressing CD39 and CD133 in acute liver injury. Transplantation. 2013;95:63–9.
Shi Q, Hong H, Senior J, et al. Biomarkers for drug-induced liver injury. Expert Rev Gastroenterol Hepatol. 2010;4:225–34.
Sohn W, Kim J, Kang SH, et al. Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma. Exp Mol Med. 2015;47:e184.
Stravitz RT, Bowling R, Bradford RL, et al. Role of procoagulant microparticles in mediating complications and outcome of acute liver injury/acute liver failure. Hepatology. 2013;58:304–13.
Sugimachi K, Matsumura T, Hirata H, et al. Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer. 2015;112:532–8.
Tan CY, Lai RC, Wong W, et al. Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem Cell Res Ther. 2014;5:76.
Taylor DD, Shah S. Methods of isolating extracellular vesicles impact down-stream analyses of their cargoes. Methods. 2015;87:3–10.
Teoh NC, Ajamieh H, Wong HJ, et al. Microparticles mediate hepatic ischemia-reperfusion injury and are the targets of Diannexin (ASP8597). PLoS One. 2014;9:e104376.
van der Pol E, Boing AN, Harrison P, et al. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev. 2012;64:676–705.
Wang W, Li H, Zhou Y, et al. Peripheral blood microvesicles are potential biomarkers for hepatocellular carcinoma. Cancer Biomark. 2013;13:351–7.
Wang H, Hou L, Li A, et al. Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed Res Int. 2014;2014:864894.
Yanez-Mo M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066.
Yang X, Weng Z, Mendrick DL, et al. Circulating extracellular vesicles as a potential source of new biomarkers of drug-induced liver injury. Toxicol Lett. 2014;225:401–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Disclaimer: The information in these materials is not a formal dissemination of information by FDA and does not represent agency position or policy.
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media Dordrecht (outside the USA)
About this entry
Cite this entry
Shi, Q. (2017). Circulating Extracellular Vesicles as Liver Biomarkers. In: Patel, V., Preedy, V. (eds) Biomarkers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7675-3_38
Download citation
DOI: https://doi.org/10.1007/978-94-007-7675-3_38
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-7674-6
Online ISBN: 978-94-007-7675-3
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences